AG真人官方

Celyad Oncology SA: Publication of a Transparency Notification Received from Fortress Investment Group LLC

(Article 14 搂1 of the Law of 2 May 2007)

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:

Celyad Oncology SA (Euronext: CYAD) (鈥淐elyad Oncology鈥� or the 鈥淐ompany鈥�) today announces, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the 鈥淭ransparency Law鈥�), that it received a notification of transparency dated August 11, 2025, indicating that CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group LLC, has crossed the statutory threshold of 60%, holding 32,691,987 voting rights, i.e. 60.96% of Celyad Oncology鈥檚 voting rights.

Content of the Notification:

• Reason of the Notification:
  Acquisition or disposal of voting securities or voting rights

• Notification by:
  A parent undertaking or a controlling person

• Persons subject to the notification requirement:
  Fortress Investment Group LLC - 1345 Avenue of the Americas, New York, NY 10105 United States
  CFIP CLYD (UK) Limited - 7 Clarges Street, 4th Floor, London W1J 8AE, United Kingdom

• Date on which the threshold is crossed:
  August 5, 2025

• Threshold that is crossed (in %):
  60

• Denominator:
  53,630,280

• Notified details:

• Full chain of controlled undertakings through which the holdings is effectively held:
  • CFIP CLYD (UK) Limited (鈥淐FIP UK鈥�), a UK limited liability company directly holds 32,691,987 voting rights in the issuer.
  • CFIP CLYD LLC, a Delaware limited liability company (鈥淐FIP鈥�), is the parent of CFIP UK.
  • FIP II UB Investments LP, a Delaware limited partnership (鈥淔IP II鈥�), holds 50% of the membership interests in CFIP.
  • FIP Fund II GP LLC, a Delaware limited liability company (鈥淔IP II GP鈥�), is the general partner of FIP II.
  • Hybrid GP Holdings LLC, a Delaware limited liability company (鈥淗ybrid GP鈥�), is the parent of FIP II GP and indirectly controls the general partners of certain investment funds that hold membership interests in CFIP.
  • FIG LLC, a Delaware limited liability company (鈥淔IG LLC鈥�), is an investment advisor registered with the US Securities and Exchange Commission and indirectly controls the investment advisers to certain investment funds that hold membership interests in CFIP.
  • Fortress Operating Entity I LP, a Delaware limited partnership (鈥淔OE I鈥�), is (i) the sole owner of FIG LLC and (ii) the managing member of, and holds the majority of equity interest in, Hybrid GP.
  • FIG Blue LLC (formerly known as FIG Corp.), a Delaware limited liability company (鈥淔IG Blue鈥�) is the general partner of FOE I.
  • Fortress Investment Group LLC, a Delaware limited liability company (鈥淔ortress鈥�) is the sole owner of FIG Blue. Fortress, acting through the investment advisers owned and controlled by FIG LLC, holds discretionary authority over the funds that indirectly hold the membership interests in CFIP, and can exercise the voting rights associated therewith without any instruction from its clients
• Additional information:
  This transparency notification covers the crossing of the 60% threshold due to a capital increase on 5 August 2025 whereby CFIP CLYD (UK) Limited received 3,333,333 additional shares of Celyad Oncology. As a result, CFIP CLYD (UK) currently holds 32,691,987 voting rights.

Miscellaneous

• The Press Release may be consulted on the website of Celyad Oncology:
  

• The notification can be consulted on the website of Celyad Oncology:
  

• Contact person(s): Any transparency notification must be sent to our Company by email to the attention of Matthew Kane, Chief Executive Officer (CEO): [email protected]

About Celyad Oncology

Celyad Oncology is a cutting-edge biotechnology company focused primarily on unlocking the potential of its proprietary CAR-T technology platforms and intellectual property. The Company is headquartered in Mont Saint-Guibert, Belgium. For more information, visit .

Forward-looking statements

This release may contain forward-looking statements, including, without limitation, statements regarding beliefs about and expectations for the Company鈥檚 updated strategic business model, including associated potential benefits, transactions and partnerships, statements regarding the potential value of the Company鈥檚 IP, statements regarding the Company鈥檚 financial statements and cash runway, statements regarding the Company鈥檚 future fundraising plans, statements regarding the Company鈥檚 hiring plans, and statements regarding the continuation of the Company鈥檚 existence. The words 鈥渨ill,鈥� 鈥減otential,鈥� 鈥渃ontinue,鈥� 鈥渢arget,鈥� 鈥減roject,鈥� 鈥渟hould鈥� and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this release are based on management鈥檚 current expectations and beliefs and are subject to a number of known and unknown risks, uncertainties and important factors which might cause actual events, results, financial condition, performance or achievements of Celyad Oncology to differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks related to the material uncertainty about the Company鈥檚 ability to continue as a going concern; the Company鈥檚 ability to realize the expected benefits of its updated strategic business model; the Company鈥檚 ability to develop its IP assets and enter into partnerships with outside parties; the Company鈥檚 ability to enforce its patents and other IP rights; the possibility that the Company may infringe on the patents or IP rights of others and be required to defend against patent or other IP rights suits; the possibility that the Company may not successfully defend itself against claims of patent infringement or other IP rights suits, which could result in substantial claims for damages against the Company; the possibility that the Company may become involved in lawsuits to protect or enforce its patents, which could be expensive, time-consuming, and unsuccessful; the Company鈥檚 ability to protect its IP rights throughout the world; the potential for patents held by the Company to be found invalid or unenforceable; and other risks identified in the latest Annual Report of Celyad Oncology. These forward-looking statements speak only as of the date of publication of this document and Celyad Oncology鈥檚 actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad Oncology expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

View source version on businesswire.com:

Celyad Oncology

Investor and Media:

David Georges

VP Finance and Administration

[email protected]

Source: Celyad Oncology SA